Core Viewpoint - Sichuan Zimuongong Pharmaceutical Co., Ltd. is focusing on innovation and market expansion while enhancing production capacity and management efficiency to drive future growth [2][3]. Group 1: Company Overview - Zimuongong has a history of 245 years and specializes in drug research, production, and marketing, holding 26 invention patents and 99 drug production approvals across various forms [2]. - The company is primarily focused on the development of drugs for the nervous system and digestive system, with future emphasis on endocrine and analgesic drugs [2]. Group 2: Financial Performance - In 2024, Zimuongong achieved a revenue of 416 million yuan, a year-on-year increase of 1.87%, and a net profit attributable to shareholders of 85.64 million yuan [3]. - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 29.31 million yuan, with the total cash dividends over the last three years amounting to about 144 million yuan, representing 149.21% of the average annual net profit [4]. Group 3: Research and Development - Zimuongong increased its R&D investment by 81.18% compared to the same period in 2023, focusing on both innovative and generic drugs [3]. - The company is advancing its innovative drug pipeline, including the initiation of clinical trials for the Ma Jia Zi capsule and the successful launch of the Phosphate Oseltamivir capsule [3]. Group 4: Future Strategy - The company aims to adhere to its core business in pharmaceutical manufacturing while driving growth through innovation and marketing, focusing on both internal growth and external expansion [4].

年报显示，公司2024年实现营业收入营业收入达4.16亿元，同比更上台阶；当期归母净利润8564.39万 元、期间毛利率78.80%，双双继续保持较高水平。 从业务布局来看，公司现已形成以神经系统类、消化系统类药品为主导，多系统药品协同发展的格局。 旗下产品丰富，如胞磷胆碱钠片销售强劲、成为公司保持业绩稳健的压舱石，此外苯甲酸利扎曲普坦胶 囊、普瑞巴林口服溶液等多个明星产品表现亮眼。 值得指出的是，研发投入加码是梓橦宫的一大鲜明底色，公司当期研发投入的营收占比高达9.55%，其 中当期资本化研发支出的比例进一步提升至73.66%，研发成果转换蹄疾步稳。 全景网了解到，公司一类创新药马甲子胶囊首例受试者入组，正式开启I期临床试验。新品种塞来昔布 胶囊、磷酸奥司他韦胶囊等陆续上市销售，新研发项目富马酸伏诺拉生片、布洛芬缓释胶囊等按计划推 进，同时还新启动地屈孕酮片、盐酸利多卡因无菌凝胶等多个项目，提前布局"十五五"产品管线。 必须看到，研发创新正持续为公司可持续发展注入强劲动力，并有望引领未来业绩迈向新高度。 报告期内，公司在市场拓展方面也持续取得新战绩：公司产品普瑞巴林口服溶液亦中选第十批全国药品 集中采购，新 ...